Increase in the prevalence of carbapenem-resistant acinetobacter isolates and ampicillin-resistant non-typhoidal Salmonella species in Korea: A KONSAR Study Conducted in 2011

Infection and Chemotherapy

Volumn 46, Issue 2, 2014, Pages 84-93

  Yong, Dongeun ^a   Shin, Hee Bong ^b   Kim, Yong Kyun ^c   Cho, Jihyun ^d   Lee, Wee Gyo ^e   Ha, Gyoung Yim ^f   Choi, Tae Yeal ^g   Jeong, Seok Hoon ^a   Lee, Kyungwon ^a   Chong, Yunsop ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Soonchunhyang University   (South Korea)

^c Samkwang Medical Laboratories   (South Korea)

^d Wonkwang University Hospital   (South Korea)

^e Ajou University School of Medicine   (South Korea)

^f Dongguk University Gyeongju Hospital   (South Korea)

^g Hanyang University College of Medicine   (South Korea)

Author keywords

Acinetobacter; Antimicrobial resistance surveillance; KONSAR; Pseudomonas aeruginosa; Staphylococcus

Indexed keywords

AMIKACIN; AMPICILLIN; ANTIINFECTIVE AGENT; AZTREONAM; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; COLISTIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MINOCYCLINE; OXACILLIN; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; SULTAMICILLIN; TEICOPLANIN; TETRACYCLINE; TOBRAMYCIN; VANCOMYCIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; HOSPITAL LABORATORY; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; KOREA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PREVALENCE; PSEUDOMONAS AERUGINOSA; SECONDARY CARE CENTER; SERRATIA MARCESCENS; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS PNEUMONIAE;

EID: 84903850861     PISSN: 20932340     EISSN: 20926448     Source Type: Journal    
DOI: 10.3947/ic.2014.46.2.84     Document Type: Article

References (22)

1. Chong Y, Lee K, Park YJ, Jeon DS, Lee MH, Kim MY, Chang CH, Kim EC, Lee NY, Kim HS, Kang ES, Cho HC, Paik IK, Lee HS, Jang SJ, Park AJ, Cha YJ, Kang SH, Lee MH, Song W, Shin JH. Korean nationwide surveillance of antimicrobial resistance of bacteria in 1997. Yonsei Med J 1998;39:569-77.
2. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement M100-S19. Wayne, PA: CLSI; 20
3. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement. CLSI document M100-S21. Wayne, PA: CLSI; 2011.
4. O'Brien TF, Stelling JM. WHONET: removing obstacles to the full use of information about antimicrobial resistance. Diagn Microbiol Infect Dis 1996;25:162-8.
5. Lee K, Lee MA, Lee CH, Lee J, Roh KH, Kim S, Kim JJ, Koh E, Yong D, Chong Y ; KONSAR Group. Increase of ceftazidime- and fluoroquinolone-resistant Klebsiella pneumoniae and imipenem-resistant Acinetobacter spp. in Korea: analysis of KONSAR study data from 2005 and 2007. Yonsei Med J 2010;51:901-11.
6. Fridkin SK, Hill HA, Volkova NV, Edwards JR, Lawton RM, Gaynes RP, McGowan JE Jr; Intensive Care Antimicrobial Resistance Epidemiology Project Hospitals. Temporal changes in prevalence of antimicrobial resistance in 23 US hospitals. Emerg Infect Dis 2002;8:697-701.
7. Van Beneden CA, Lexau C, Baughman W, Barnes B, Bennett N, Cassidy PM, Pass M, Gelling L, Barrett NL, Zell ER, Whitney CG. Aggregated antibiograms and monitoring of drug-resistant Streptococcus pneumoniae. Emerg Infect Dis 2003;9:1089-95.
8. Sahm DF, Marsilio MK, Piazza G. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database--USA. Clin Infect Dis 1999;29:259-63.
9. Felmingham D, Grüneberg RN. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000;45:191-203.
10. Clinical and Laboratory Standards Institute. Analysis and presentation of cumulative antimicrobial susceptibility test data; approved guideline-Third Edition, M39-A3. Wayne, PA: CLSI; 2008.
11. Zhanel GG, DeCorby M, Laing N, Weshnoweski B, Vashisht R, Tailor F, Nichol KA, Wierzbowski A, Baudry PJ, Karlowsky JA, Lagacé-Wiens P, Walkty A, McCracken M, Mulvey MR, Johnson J, Canadian Antimicrobial Resistance Alliance (CARA), Hoban DJ. Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. Antimicrob Agents Chemother 2008;52:1430-7.
12. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003;289:885-8.
13. Rosenthal VD, Maki DG, Jamulitrat S, Medeiros EA, Todi SK, Gomez DY, Leblebicioglu H, Abu Khader I, Miranda Novales MG, Berba R, Ramírez Wong FM, Barkat A, Pino OR, Dueñas L, Mitrev Z, Bijie H, Gurskis V, Kanj SS, Mapp T, Hidalgo RF, Ben Jaballah N, Raka L, Gikas A, Ahmed A, Thu le TA, Guzmán Siritt ME; INICC Members. International Nosocomial Infection Control Consortium (INICC) report, data summary for 2003-2008, issued June 2009. Am J Infect Control 2010;38:95-104, e2.
14. Lee K, Kim MN, Kim JS, Hong HL, Kang JO, Shin JH, Park YJ, Yong D, Jeong SH, Chong Y; KONSAR Group. Further increases in carbapenem-, amikacin-, and fluoroquinolone-resistant isolates of Acinetobacter spp. and P. aeruginosa in Korea: KONSAR study 2009. Yonsei Med J 2011;52:793-802.
15. Bae S, Lee J, Lee J, Kim E, Lee S, Yu J, Kang Y. Antimicrobial resistance in Haemophilus influenzae respiratory tract isolates in Korea: results of a nationwide acute respiratory infections surveillance. Antimicrob Agents Chemother 2010;54:65-71.
16. Lee K, Kim MN, Choi TY, Cho SE, Lee S, Whang DH, Yong D, Chong Y, Woodford N, Livermore DM. Wide dissemination of OXA-type carbapenemases in clinical Acinetobacter spp. isolates from South Korea. Int J Antimicrob Agents 2009;33:520-4.
17. Ko KS, Suh JY, Kwon KT, Jung SI, Park KH, Kang CI, Chung DR, Peck KR, Song JH. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother 2007;60:1163-7.
18. Lee K, Yong D, Jeong SH, Chong Y. Multidrug-resistant Acinetobacter spp.: increasingly problematic nosocomial pathogens. Yonsei Med J 2011;52:879-91.
19. Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 2012;67:1607-15.
20. Sung H, Choi SJ, Yoo S, Kim MN. In vitro antimicrobial synergy against imipenem-resistant Acinetobacter baumannii. Korean J Lab Med 2007;27:111-7.
21. Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother 2012;67:1597-606.
22. Potron A, Rondinaud E, Poirel L, Belmonte O, Boyer S, Camiade S, Nordmann P. Genetic and biochemical characterisation of OXA-232, a carbapenem-hydrolysing class D ß-lactamase from Enterobacteriaceae. Int J Antimicrob Agents 2013;41:325-9.